As of June 13, 2025, Generex Biotechnology Corp (GNBT) reports a EV/EBITDA of -0.20.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Generex Biotechnology Corp's EV/EBITDA to Peers
To better understand Generex Biotechnology Corp's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Generex Biotechnology Corp (GNBT) | -0.20 |
| Enzon Pharmaceuticals Inc (ENZN) | 59.61 |
| Q BioMed Inc (QBIO) | 11.32 |
| Navidea Biopharmaceuticals Inc (NAVB) | 0.30 |
| Xenetic Biosciences Inc (XBIO) | 0.08 |
| American Cryostem Corp (CRYO) | -0.23 |
Compared to its competitors, Generex Biotechnology Corp's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.